Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
247.76
-8.76 (-3.41%)
Aug 11, 2026, 12:05 PM EDT - Market open

Jazz Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
940.75-356.15560.12414.83-224.06-329.67
Depreciation & Amortization
718696.3660.07638.7629.47552.48
Stock-Based Compensation
306.73291.13248.05226.84222189.01
Other Adjustments
-256.01705.594.416.08634.67414.64
Change in Receivables
-168.18-106.28-21.12-51.88-90.14-92.74
Changes in Inventories
-131.84-86.04-45.54-13.42-49.64-48.86
Changes in Accounts Payable
40.4539.85-20.079.6-11.2357.02
Changes in Accrued Expenses
153.177.186.16-23.25165.99142.36
Changes in Income Taxes Payable
-22.3837.22-14.7425.22-1.69-15.52
Changes in Unearned Revenue
-----2.09-2.31
Changes in Other Operating Activities
14.5257.05-61.41-150.71-1.3-87.9
Operating Cash Flow
1,6611,3561,3961,0921,272778.51
Operating Cash Flow Growth
26.23%-2.88%27.83%-14.15%63.39%-13.46%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-69.75-58.75-38.07-23.96-29.05-27.64
Purchases of Intangible Assets
-203-151-10-19-469.15-17.89
Proceeds from Sale of Intangible Assets
122.8-----
Purchases of Investments
-1,920-1,830-1,305-390.1-61.04-26.82
Proceeds from Sale of Investments
1,8201,360845270601,095
Cash Acquisitions
0.05-858.05----6,235
Proceeds from Business Divestments
-28.17--53-
Investing Cash Flow
-221.91-1,510-508.2-163.06-446.23-5,212

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--980.77--5,191
Long-Term Debt Repaid
--781-606-31-582.01-1,321
Net Long-Term Debt Issued (Repaid)
--781374.77-31-582.013,871
Issuance of Common Stock
141.46107.8620.6546.4698.02135.26
Repurchase of Common Stock
-0.02-125.02-311.43-269.76-0.05-
Net Common Stock Issued (Repurchased)
141.44-17.16-290.78-223.397.97135.26
Other Financing Activities
-118.92-75.22-63.47-50.95-45.44-35.6
Financing Cash Flow
-1,008-873.3820.52-305.25-529.493,971

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.756.56-1.681.14-6.22-3.21
Net Cash Flow
429.94-1,021906.55624.83290.03-466.32

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,5911,2971,3581,0681,243750.87
Free Cash Flow Growth
25.79%-4.48%27.13%-14.07%65.53%-15.12%
FCF Margin
34.58%30.39%33.37%27.86%33.97%24.27%
Free Cash Flow Per Share
24.4321.2720.5714.8219.8712.58
Levered Free Cash Flow
1,643-374.431,501846.01-105.614,111
Unlevered Free Cash Flow
1,862519.171,4221,274662.821,066
SEC Filings: 10-K · 10-Q